Efficacy and tolerability of nonpenetrating glaucoma surgery augmented with mitomycin C in treatment of open-angle glaucoma: a meta-analysis

2009 ◽  
Vol 44 (1) ◽  
pp. 76-82 ◽  
Author(s):  
Jin-Wei Cheng ◽  
Gui-Lin Xi ◽  
Rui-Li Wei ◽  
Ji-Ping Cai ◽  
You Li
2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Jeffrey T. Y. Chow ◽  
Cindy M. L. Hutnik ◽  
Karla Solo ◽  
Monali S. Malvankar-Mehta

The purpose of this systematic review and meta-analysis was to examine the availability of evidence for one of the earliest available minimally invasive glaucoma surgery (MIGS) procedures, the Trabectome. Various databases were searched up to December 20, 2016, for any published studies assessing the use of the Trabectome as a solo procedure in patients with primary open-angle glaucoma (POAG). The standardized mean differences (SMD) were calculated for the change in intraocular pressure (IOP) and number of glaucoma mediations used at 1-month, 6-month, and 12-month follow-up. After screening, three studies and one abstract with analyzable data were included. The meta-analysis showed statistically significant reductions in IOP and number of glaucoma medications used at all time points. Though the Trabectome as a solo procedure appears to lower IOP and reduces the number of glaucoma medications, more high-quality studies are required to make definitive conclusions. The difficulty of obtaining evidence may be one of the many obstacles that limit a full understanding of the potential safety and/or efficacy benefits compared to standard treatments. The time has come for a thoughtful and integrated approach with stakeholders to determine optimal access to care strategies for our patients.


Author(s):  
Laura Denkel ◽  
Bettina Hohberger ◽  
Robert Lämmer

Abstract Purpose Minimally invasive glaucoma surgery (MIGS), like Xen45 gel stents, is known as effective therapy in lowering intraocular pressure (IOP); however, fibrotic reactions are a common problem in postoperative management. It was the aim of this study to investigate the therapeutic success of Xen45 gel stents as a stand-alone technique (Xen) and combined with cataract surgery (XenPhaco), and with antimetabolites (mitomycin C, MMC) in open-angle glaucoma patients. Methods Retrospective analysis was performed of 199 eyes of 177 glaucoma patients of the Department of Ophthalmology, University of Erlangen Nürnberg, and from the Erlangen Glaucoma Registry (NCT00494923; ISSN 2191-5008, CS-2011) who underwent implantation of a Xen45 gel stent. Therapeutic success was defined as IOP reduction of ≥ 20% on the same or less anti-glaucomatous medication after 12 months compared to preoperative and without any additional glaucoma-related surgery (except bleb needling). IOP reduction, reduction in local anti-glaucomatous eye drops, and intra- and postoperative complications were monitored. Results Stand-alone Xen45 gel stent: therapeutic success was reached in 39% (–MMC) and 55% (+MMC). Failure rate was 61% (–MMC) and 45% (+MMC). XenPhaco: therapeutic success was achieved in 57% (–MMC) and 46% (+MMC). Failure rate was 43% (-MMC) and 54% (+MMC). Data were not different for group and subgroup analyses (p > 0.05). Conclusions The use of MMC seemed to increase the therapeutic success rate after stand-alone Xen45 gel stent implantation and combined with cataract surgery, yet statistical significant was not reached.


Ophthalmology ◽  
1999 ◽  
Vol 106 (7) ◽  
pp. 1357-1362 ◽  
Author(s):  
Luciano Quaranta ◽  
Roger A. Hitchings ◽  
Carlo A. Quaranta

2014 ◽  
Vol 36 (1) ◽  
pp. 27-30 ◽  
Author(s):  
Rong Zhao ◽  
Dongchen Yin ◽  
Enpu Wang ◽  
Bingxin Si

PLoS ONE ◽  
2014 ◽  
Vol 9 (9) ◽  
pp. e108226 ◽  
Author(s):  
Hyoung Won Bae ◽  
Naeun Lee ◽  
Hye Sun Lee ◽  
Samin Hong ◽  
Gong Je Seong ◽  
...  

2017 ◽  
Vol 57 (4) ◽  
pp. 230-238 ◽  
Author(s):  
Fathi El-Sayyad ◽  
Heba Magdy Ahmed El-Saied ◽  
Mohamad Amr Salah Eddin Abdelhakim

2020 ◽  
Vol 9 (10) ◽  
pp. 3172 ◽  
Author(s):  
Stefania Vernazza ◽  
Sara Tirendi ◽  
Anna Maria Bassi ◽  
Carlo Enrico Traverso ◽  
Sergio Claudio Saccà

Primary open-angle glaucoma (POAG) is the second leading cause of irreversible blindness worldwide. Increasing evidence suggests oxidative damage and immune response defects are key factors contributing to glaucoma onset. Indeed, both the failure of the trabecular meshwork tissue in the conventional outflow pathway and the neuroinflammation process, which drives the neurodegeneration, seem to be linked to the age-related over-production of free radicals (i.e., mitochondrial dysfunction) and to oxidative stress-linked immunostimulatory signaling. Several previous studies have described a wide range of oxidative stress-related makers which are found in glaucomatous patients, including low levels of antioxidant defences, dysfunction/activation of glial cells, the activation of the NF-κB pathway and the up-regulation of pro-inflammatory cytokines, and so on. However, the intraocular pressure is still currently the only risk factor modifiable by medication or glaucoma surgery. This present review aims to summarize the multiple cellular processes, which promote different risk factors in glaucoma including aging, oxidative stress, trabecular meshwork defects, glial activation response, neurodegenerative insults, and the altered regulation of immune response.


Sign in / Sign up

Export Citation Format

Share Document